|
Hot Stocks
| ShowHide Related Items >><< - 01/18/22
- Fortuna Silver Mines sees FY21 gold production 244,000-280,000 ounces
- 01/18/22
- Fortuna Silver produces 1.98M ounces of silver, 76,162 ounces of gold in Q4
- 01/18/22
- Fortuna Silver produces 7.5M ounces of silver, 207,192 ounces of gold in FY21
- 12/20/21
- Fortuna Silver Mines rises 16.9%
- 01/19/22 Canaccord
- Fortuna Silver Mines price target lowered to C$5.50 from C$6 at Canaccord
- 01/19/22 BMO Capital
- Fortuna Silver Mines price target lowered to C$6.50 from C$7.25 at BMO Capital
- 01/18/22 Canaccord
- Fortuna Silver Mines upgraded to Buy from Hold at Canaccord
- 12/20/21 BMO Capital
- Fortuna Silver upgraded to Outperform from Market Perform at BMO Capital
- 11/11/21
- Fortuna Silver Mines reports Q3 EPS 0c, consensus 15c
- 08/11/21
- Fortuna Silver Mines reports Q2 EPS 9c vs 12c last year
- 12/20/21
- Wall Street in Fives - Must Read Lists for Monday
- 12/20/21
- Wall Street in Fives - Must Read Lists at Midday
|
|
Conference/Events
| |
|
Conference/Events
| ShowHide Related Items >><< - 01/10/22
- BioCryst says BCX9930 pivotal trials in PHN now enrolling
- 01/07/22
- BioCryst begins patient enrollment in REDEEM-1 trial of BCX9930 for PNH
- 12/03/21
- BioCryst reports inducement grants under Nasdaq listing rule
- 12/02/21
- Praxis Precision Medicines appoints Megan Sniecinski as CBO
TAK Takeda Pharmaceutical - 01/19/22
- Sangamo CEO says preclinical studies moving forward 'beautifully'
- 01/10/22
- Takeda Pharmaceutical to acquire Adaptate Biotherapeutics
- 12/21/21
- Takeda Pharmaceutical receives CRL from FDA for TAK-721
- 12/17/21
- Takeda receives 'positive' CHMP opinion for vedolizumab IV
IONS Ionis Pharmaceuticals - 07:06 Today
- Ionis Pharmaceuticals: Eplontersen gets orphan drug designation from U.S. FDA
- 01/19/22
- Ionis Pharmaceuticals announces two leadership team appointments
- 01/18/22
- Ionis Pharmaceuticals partner Roche to design new tominersen trial
- 01/06/22
- Ionis Pharmaceuticals' eplontersen granted FDA orphan designation
- 07:32 Today
- KalVista publishes KVD900 data in JACI
- 11/10/21
- KalVista provides update on clinical trial progress for KVD900
- 11/08/21
- KalVista announces data at ACAAI from Phase 2 data for KVD900
- 09/14/21
- KalVista says FDA lifts clinical hold on Phase 2 clinical trial of KVD824
- 12/22/21
- Pharvaris announces changes to board of directors
- 12/07/21
- Pharvaris announces changes to board of directors
NTLA Intellia Therapeutics - 01/06/22
- Intellia Therapeutics highlights strategic priorities, milestones for 2022
- 01/05/22
- Cathie Wood's ARK Investment bought 168.7K shares of Intellia Therapeutics today
- 01/05/22
- Intellia Therapeutics, Kyverna announce collaboration to develop KYV-201
- 12/20/21
- Intellia Therapeutics appoints Derek Hicks as CBO
- 12/16/21
- Vifor Pharma divests finished drug manufacturing business to CordenPharma
- 12/15/21
- CSL: EMA grants approval for etranacogene dezaparvovec MAA
- 12/14/21
- CSL to acquire Vifor Pharma in all-cash tender offer of $179.25 per share
- 12/02/21
- Vifor says regularly in talks with other market participants after reports
- 12/09/21 Oppenheimer
- Oppenheimer starts 'underappreciated' BioCryst at Outperform
- 12/09/21 Oppenheimer
- BioCryst initiated with an Outperform at Oppenheimer
- 11/22/21 Piper Sandler
- BioCryst financing lifts one of two overhangs, says Piper Sandler
- 11/04/21 Barclays
- BioCryst price target lowered to $17 from $21 at Barclays
TAK Takeda Pharmaceutical - 01/13/22 Goldman Sachs
- Takeda Pharmaceutical downgraded to Neutral from Buy at Goldman Sachs
- 10/29/21 Jefferies
- Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
- 10/12/21 Piper Sandler
- Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
- 10/06/21 Morgan Stanley
- Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
IONS Ionis Pharmaceuticals - 12/28/21 Oppenheimer
- Ionis weakness associated with peer ATTR failure 'misplaced,' says Oppenheimer
- 12/14/21 William Blair
- Ionis upgraded to Outperform on pipeline opportunities at William Blair
- 12/14/21 William Blair
- Ionis Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
- 11/26/21 Mizuho
- Pfizer data on vupanorsen is mixed, says Mizuho
- 11/10/21 Roth Capital
- KalVista FDA meeting feedback 'quite positive,' says Roth Capital
- 08/23/21 Roth Capital
- KalVista could take 'substantial' share of HAE market, says Roth Capital
- 04/20/21 Roth Capital
- KalVista selloff seems overdone after clinical hold, says Roth Capital
- 02/17/21 Roth Capital
- KalVista price target raised to $55 from $30 at Roth Capital
- 07/02/21 Wedbush
- Pharming collaboration offers upside for Orchard Therapeutics, says Wedbush
- 03/02/21 SVB Leerink
- Pharvaris initiated with an Outperform at SVB Leerink
- 03/02/21 Oppenheimer
- Pharvaris initiated with an Outperform at Oppenheimer
- 03/02/21 Morgan Stanley
- Pharvaris initiated with an Overweight at Morgan Stanley
- 03/02/21 SVB Leerink
- Pharvaris initiated with an Outperform at SVB Leerink
NTLA Intellia Therapeutics - 01/07/22 JMP Securities
- Intellia Therapeutics price target lowered to $165 from $175 at JMP Securities
- 01/07/22 Piper Sandler
- Intellia Therapeutics initiated with an Overweight at Piper Sandler
- 11/16/21 Roth Capital
- Intellia given authorization for hereditary angioedema trial, says Roth Capital
- 11/09/21 Benchmark
- Benchmark sees signs Regeneron may be planning large acquisition
- 09/29/21
- Fly Intel: Top five analyst initiations
- 09/29/21 Jefferies
- Astria Therapeutics initiated with a Buy at Jefferies
- 10/05/21 Jefferies
- CSL upgraded to Buy from Hold at Jefferies
- 08/18/21 Jefferies
- CSL downgraded to Hold from Buy at Jefferies
- 06/24/21 Credit Suisse
- CSL downgraded to Neutral from Outperform at Credit Suisse
- 06/23/21 Citi
- CSL downgraded to Neutral from Buy at Citi
- 01/10/22
- BioCryst sees 2022 ORLADEYO revenue no less than $250M
- 01/10/22
- BioCryst sees 2021 ORLADEYO revenue $122M
- 01/10/22
- BioCryst sees Q4 ORLADEYO revenue $35.6M
- 11/03/21
- BioCryst sees current cash runway funding operations into 2023
IONS Ionis Pharmaceuticals - 11/03/21
- Ionis Pharmaceuticals reports Q3 EPS (58c), consensus (52c)
- 08/04/21
- Ionis Pharmaceuticals sees FY21 net loss less than ($110M)
- 08/04/21
- Ionis Pharmaceuticals reports Q2 EPS (57c), consensus (58c)
- 12/09/21
- KalVista reports Q2 EPS (80c), consensus (79c)
- 09/09/21
- KalVista reports Q1 EPS (66c), consensus (71c)
- 11/10/21
- Pharvaris reports Q3 EPS (EUR0.39) vs. (EUR1.32) last year
- 07/30/21
- Pharvaris reports Q2 EPS (EUR0.94) vs. (EUR1.19) last year
NTLA Intellia Therapeutics - 11/04/21
- Intellia Therapeutics reports Q3 EPS (97c), consensus (84c)
- 08/05/21
- Intellia Therapeutics reports Q2 EPS ($1.01), consensus (63c)
- 11/10/21
- Astria Therapeutics reports Q3 EPS (61c), consensus (77c)
|
|
On The Fly
| ShowHide Related Items >><< - $895.99 /
-47.01 (-4.99%) - 01/18/22
- EU passenger car registrations down 22.8% in December
- 01/14/22
- 'Tesla merch buyable with Dogecoin,' Elon Musk says via Twitter
- 01/10/22
- Talon Metals announces nickel supply agreement with Tesla
- 01/07/22
- Tesla CEO says FSD price rising to $12,000 on January 17
- 01/21/22
- GM to invest about $154M in Western New York plant for electric motor parts
- 01/20/22
- GM sees delivery of electric Cadillac LYRIQ to customers in a 'few months'
- 01/19/22
- GM announces new applications of HYDROTEC fuel cell technology
- 01/19/22
- Honda, SES Holdings enter joint development agreement for Li-Metal batteries
- 01/18/22
- Blink Charging deploying EV chargers at GM dealerships in U.S. and Canada
- 01/18/22
- Blink Charging to supply electric vehicle chargers to GM dealerships
- 12/28/21
- Blink Charging says will unveil seven new products at CES
- 12/20/21
- U.S. EPA finalizes new vehicle emissions requirements
- 01/20/22
- Nikola, Corcentric Fleet Funding Solutions announce partnership
- 01/18/22
- Nikola, Proterra announce multi-year supply agreement
- 01/13/22
- Nikola's Tre BEV approved by CARB as zero-emission vehicle
- 01/13/22
- Xos appoints Mike Chaffins as VP of Supply Chain
- 01/18/22
- Nikola, Proterra announce multi-year supply agreement
- 01/13/22
- Proterra battery technology to power Vicinity Motor electric buses, trucks
- 01/09/22
- Fly Intel: Top five weekend stock stories
- 12/14/21
- Proterra announces EV battery factory in South Carolina
- $895.99 /
-47.01 (-4.99%) - 01/20/22 Jefferies
- Tesla 2022-23 estimates raised at Jefferies ahead of Q4 report
- 01/19/22 Piper Sandler
- Tesla will continue exceeding profitability expectations, says Piper Sandler
- 01/18/22 Credit Suisse
- Tesla price target raised to $1,025 from $830 at Credit Suisse
- 01/12/22 New Street
- New Street sees 50% upside in Tesla this year amid 'perfect storm'
- 06:34 Today BofA
- Bofa adds two, removes three from best investment ideas list
- 01/13/22 Deutsche Bank
- Deutsche Bank sees 2022 guidance misses from these auto companies
- 01/13/22 Deutsche Bank
- General Motors price target raised to $71 from $67 at Deutsche Bank
- 01/05/22 Citi
- Citi has 'mixed' views on GM's Silverado electric vehicle
- 11/22/21
- Fly Intel: Top five analyst downgrades
- 11/22/21 Cowen
- Blink Charging downgraded to Market Perform from Outperform at Cowen
- 11/15/21
- Fly Intel: Top five analyst upgrades
- 11/15/21 DA Davidson
- Blink Charging price target raised to $35 from $31 at DA Davidson
- 11/08/21 Wedbush
- Nikola price target raised to $15 from $10 at Wedbush
- 11/05/21 BTIG
- Nikola downgraded to Neutral from Buy at BTIG
- 09/09/21 JPMorgan
- Nikola price target lowered to $12 from $21 at JPMorgan
- 08/11/21
- Fly Intel: Top five analyst initiations
- 06:12 Today Citi
- Proterra price target lowered to $10 from $15 at Citi
- 11/12/21 Barclays
- Proterra price target raised to $11 from $10 at Barclays
- 10/22/21 Morgan Stanley
- Proterra initiated with an Equal Weight at Morgan Stanley
- 09/24/21 Barclays
- Proterra initiated with an Equal Weight at Barclays
- $895.99 /
-47.01 (-4.99%) - 10/20/21
- Tesla reports Q3 non-GAAP EPS $1.86, consensus $1.58
- 10/20/21
- Notable companies reporting after market close
- 07/30/21
- Musk sides with Epic, says Apple fees 'de facto global tax' on internet
- 07/26/21
- Tesla reports Q2 non-GAAP EPS $1.45, consensus 96c
- 12/01/21
- General Motors raises FY21 adjusted EBIT view to about $14B from $11.5B-$13.5B
- 10/27/21
- GM Financial reports Q3 net income $822M vs. $893M last year
- 10/27/21
- GM says on track for FY21 EBIT-adjusted earnings approaching high end of view
- 10/27/21
- General Motors reports Q3 adjusted EPS $1.52, consensus 96c
- 11/11/21
- Blink Charging reports Q3 EPS (36c), consensus (29c)
- 08/11/21
- Blink Charging reports Q2 EPS (32c), consensus (16c)
- 11/04/21
- Nikola reports Q3 EPS (68c), consensus (27c)
- 11/03/21
- Notable companies reporting before tomorrow's open
- 11/03/21
- Notable companies reporting before tomorrow's open
- 08/03/21
- Nikola reports Q2 adjusted EPS (20c), consensus (29c)
- 11/10/21
- Proterra sees FY21 revenue $246M, consensus $244.06M
- 11/10/21
- Proterra reports Q3 EPS (42c), consensus (16c)
- $895.99 /
-47.01 (-4.99%) - 06:03 Today
- Panasonic to start producing new Tesla batteries next year, Nikkei reports
- 01/19/22
- Tesla investors want Musk to repay $13B for SolarCity deal, Reuters reports
- 01/18/22
- Tesla asked law firm to fire attorney hired from SEC, WSJ reports
- 01/13/22
- Tesla pushes Cybertruck production start to early 2023, Reuters reports
- 01/21/22
- GM expected to announce $6.5B Michigan investment, Detroit News says
- 01/03/22
- GM, Volkswagen invest, build their battery supply chains, WSJ reports
- 12/23/21
- More companies announce no shows for in-person CES amid Covid jump, Reuters says
- 12/22/21
- Amazon, other technology firms drop CES plans due to omicron, Reuters reports
- 11/07/21
- EV charging stations win jolt of energy in Congress, WSJ says
- 01/10/22
- Rivian COO leaves amid December's production ramp, WSJ reports
- 01/05/22
- Nikola will not move forward with $2B lawsuit against Tesla, Bloomberg reports
- 10/01/21
- Nikola $2B suit against Tesla shelved by judge, Verge reports
- 08/11/21
- Senate puts $40,000 cap on price of EV qualifying for tax credit, Electrek says
- 01/08/22
- Proterra looking like a bargain, Barron's says
- $895.99 /
-47.01 (-4.99%) - 01/19/22
- Wall Street in Fives - Must Read Lists at Midday
- 01/18/22
- Wall Street in Fives - Must Read Lists at Midday
- 01/18/22
- Charged: Tesla pushes Cybertruck production start to early 2023
- 01/14/22
- Wall Street in Fives - Must Read Lists for Friday
- 01/21/22
- Wall Street in Fives - Must Read Lists for Friday
- 01/18/22
- Charged: Tesla pushes Cybertruck production start to early 2023
- 01/04/22
- Wall Street in Fives - Must Read Lists for Tuesday
- 01/04/22
- Wall Street in Fives - Must Read Lists at Midday
- 11/22/21
- Wall Street in Fives - Must Read Lists for Monday
- 11/22/21
- Charged: Ford not planning to make EV with Rivian anymore
- 11/22/21
- Wall Street in Fives - Must Read Lists at Midday
- 11/22/21
- Fly Intel: Pre-market Movers
- 01/13/22
- Wall Street in Fives - Must Read Lists for Thursday
- 01/13/22
- Wall Street in Fives - Must Read Lists at Midday
- 01/10/22
- Charged: Nikola drops suit against Tesla, Musk says FSD Beta 10.9 ready soon
- 01/05/22
- Wall Street in Fives - Must Read Lists for Wednesday
- $895.99 /
-47.01 (-4.99%) - 08:55 Today
- Notable open interest changes for January 24th
- 01/18/22
- Notable open interest changes for January 18th
- 01/13/22
- Notable open interest changes for January 13th
- 01/12/22
- Notable open interest changes for January 12th
- 01/21/22
- Unusual call flow in option market yesterday
- 01/20/22
- Size call spread bought in General Motors as shares rebound
- 01/20/22
- Sweep Call Buyer lays out $280k in General Motors will capture earnings
- 01/05/22
- General Motors call buyer realizes 25% same-day gains
- 01/21/22
- Largest borrow rate increases among liquid names
- 01/18/22
- Largest borrow rate increases among liquid names
- 01/13/22
- Largest borrow rate increases among liquid names
- 01/12/22
- Largest borrow rate increases among liquid names
- 01/06/22
- Nikola call volume above normal and directionally bullish
- 01/05/22
- Unusually active option classes on open January 5th
- 12/27/21
- Unusually active option classes on open December 27th
- 12/23/21
- Nikola call volume above normal and directionally bullish
- 11/08/21
- Unusually active option classes on open November 8th
- 10/28/21
- Largest borrow rate increases among liquid names
- 09/28/21
- Proterra call volume above normal and directionally bullish
- 08/06/21
- Proterra call volume above normal and directionally bullish
|
|
Conference/Events
|
Travel Services Analysts,… |
